Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 25, 2025

Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care

Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.

Continue
The initiative aims to harness biological and clinical insights, identify new drug targets, and create therapeutics for the oncology sector. Credit: National Cancer Institute on Unsplash.
April 24, 2025

NICE issues final guidance endorsing Pharming’s APDS therapy

The oral therapy is now accessible and funded in England via the Innovative Medicines Fund. Credit: Hal Gatewood on Unsplash.
April 23, 2025

Ensem Therapeutics’ application for ETX-636 secures FDA clearance

The company utilises its Kinetic Ensemble platform to develop precision medicines for oncology. Credit: National Cancer Institute on Unsplash.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Viatris files applications in Japan for approval of Effexor to treat GAD
  2. US FDA clears Calidi’s CLD-201 for clinical development in solid tumours
  3. Glycomine secures $115m funding for Phase IIb trial of rare disease drug
  4. Norgine agrees to acquire Theravia
  5. INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms

PRESS RELEASES

LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation